ROCKET PHARMACEUTICALS, INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $RCKT in the last 30 days.
See all $RCKT insider activity →Rocket Companies, led by Dan Gilbert, pledged $10M to a White House ballroom fund three weeks after regulators approved its $14.2B acquisition of Mr. Cooper Group. The timing has raised scrutiny, though Rocket denies any connection. The combined entity now services about 10M mortgages, or 15% of the U.S. market, according to industry reports.
StoneX kept a Buy rating on Rocket Companies with a $16.00 price target, suggesting 47.7% upside from the Oct 13 close. The firm cited market share growth and resilient revenue streams as key strengths, according to their analyst note.
Rocket Companies, Inc.'s average stock price target was reduced by analysts from $16.77 to $16.54, with a range of $12.5 to $21. This implies a 44% upside from the Oct. 9 closing price. The consensus rating remains 'Buy' among 18 analysts, with 10 Buys, 8 Holds, and 0 Sells.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning RCKT (ROCKET PHARMACEUTICALS, INC.). Coverage has been balanced: 1 bullish, 1 neutral, and 1 bearish.
Recent RCKT coverage spans financial news, regulation and market movers.
The donation may raise political‑risk concerns and attract regulatory scrutiny, potentially weighing on the stock.
Analyst rating maintenance with an elevated price target may lift the stock as investors price in upside potential.
Target cut may temper short-term optimism but still shows upside potential.
Adoption may boost Rocket's loan origination volume and improve margins as scoring costs decline.
Upgrade and higher target provide upside bias.
AlphAI scores every news story that mentions RCKT with an AI model for sentiment and relevance, and aggregates insider trades from ROCKET PHARMACEUTICALS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Rocket Companies, led by Dan Gilbert, pledged $10M to a White House ballroom fund three weeks after regulators approved its $14.2B acquisition of Mr. Cooper Group. The timing has raised scrutiny, though Rocket denies any connection. The combined entity now services about 10M mortgages, or 15% of the U.S. market, according to industry reports.
2 min readStoneX kept a Buy rating on Rocket Companies with a $16.00 price target, suggesting 47.7% upside from the Oct 13 close. The firm cited market share growth and resilient revenue streams as key strengths, according to their analyst note.
1 min readRocket Companies, Inc.'s average stock price target was reduced by analysts from $16.77 to $16.54, with a range of $12.5 to $21. This implies a 44% upside from the Oct. 9 closing price. The consensus rating remains 'Buy' among 18 analysts, with 10 Buys, 8 Holds, and 0 Sells.
1 min readThe Federal Housing Finance Agency approved VantageScore 4.0 for loans sold to Fannie Mae and Freddie Mac, potentially scoring 33 million more Americans than FICO. Rocket Mortgage adopted the new model, citing FHFA's encouragement of competition. FICO's stock dropped on the news, indicating investor awareness of potential pricing impacts.
2 min readU.S. stock futures fell on Thursday due to rising oil prices and Treasury yields. Palantir (PLTR) rose 2.3% after a bullish call with a $250 target. NXP (NXPI) fell 2.6% following a downgrade and $110 target cut. Nova (NVMI) slipped 2.9% after a downgrade and insider sales. Rocket Pharma (RCKT) climbed 2.8% on an upgrade and positive clinical data. Wolfspeed (WOLF) jumped 17% on a $1.5B loan announcement.
3 min readRocket Pharmaceuticals secured up to $150 million in financing from Hercules Capital, including an initial $35 million. The funds will support a pivotal Phase 2 study for its gene therapy candidate RP-A501 for Danon disease and broader cardiovascular pipeline development. The company reported $283.7 million in cash as of June 30, 2026, and expects the financing to extend its cash runway.
2 min readGoldman Sachs upgraded Rocket Pharmaceuticals (RCKT) to Neutral from Sell, raising its price target to $4 from $3. The upgrade follows the company's update on RP-A501 for Danon disease, which provided support for its clinical and commercial outlook. However, Goldman remains cautious about the drug's commercial potential and peak sales guidance of $1B-$2B.
2 min readLeerink Partners kept a Market Perform rating and $4 price target for Rocket Pharmaceuticals, implying a 61.3% upside from the Oct 6 close. The firm cited commercial viability concerns and regulatory/financial risks as reasons for its cautious outlook. Recent analyst price targets for RCKT range from $9 to $15.
1 min readFuelCell Energy (FCEL) shares dropped 15% after announcing a CFO transition. Ondas (ONDS) fell 5% despite $165M in new orders. Ultragenyx (RARE) rose 3.2% after selling a priority review voucher for $210M. TNR Gold (TNR) received an acquisition proposal from Altius (ALS). Rocket Pharma (RCKT) gained 4% after securing a $150M credit facility. Sigma Lithium (SGML) resumed operations after court approval. Hess Midstream (HESM) fell 16% after Chevron deal.
3 min readWedbush reiterated an Outperform rating and $15 price target for Rocket Pharmaceuticals, implying a 504.8% upside from its Oct 6 close. The firm cited strong pipeline updates, including RP-A501 for Danon disease, and an extended cash runway to 2029 due to a $150M credit facility with Hercules Capital.
1 min read
